Secondary analysis of the NADIM II trial in 60 patients with resectable NSCLC: detectable MRD after surgery or during adjuvant treatment was associated with worse event-free (HR 10.2) and overall survival (HR 10.0), including in patients without pCR.
Secondary analysisn = 60
Provencio et al. Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer